The Latest
-
Why AlphaFold 3 is stirring up so much buzz in pharma
The “Nobel Prize-worthy invention” could be worth hundreds of billions commercially — and have a deep impact on drug R&D.
-
Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies
Planning early, staying nimble and approaching commercialization as a team sport should be top priorities, the leaders said.
-
Investors put $400M into biotech licensing obesity drugs from China
The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.
-
Why H5N1 has scientists and regulators on edge
While the H5N1 threat to humans is still low, the recent influenza outbreak in cattle is presenting strange and challenging hurdles for containment.
-
Big Pharma leaders juggle pricing and access as IRA and supply constraints loom large
Execs from J&J, Novartis, Novo Nordisk and AbbVie sound off on the Inflation Reduction Act, supply issues and launch preparations in a tricky environment.
-
As Lilly surges, headwinds against its weight loss drugs are growing
After missing analysts’ earnings expectations for Mounjaro sales in the first quarter due to overwhelming demand, Lilly is also dealing with a legal loss and incoming pricing questions from lawmakers.
-
Big Pharma’s most improved drugs: a new generation of blockbusters
The old guard of pharma bestsellers is seeing more competition, but newer drugs demonstrating sales and revenue growth can build up the coffers in years to come.
-
Biosimilars are gaining ground. The IRA could push them even further next year.
As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.
-
5 trends impacting drug spend in the U.S.
Key factors changing how much Americans spend on prescriptions.
-
Q&A
The Enhertu effect: Daiichi’s plan to build on the success of its crown jewel
The CEO of Daiichi Sankyo’s American business explains why it could be poised to become a “top 10” cancer company.
-
Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown
The FDA announced a June advisory committee date, potentially introducing a new Alzheimer’s treatment to compete with Eisai and Biogen’s Leqembi.
-
Opinion
The judicial microscope on abortion meds puts FDA and industry in a precarious spot
The recent SCOTUS case involving mifepristone exposes the risk of drug safety determinations by judicial fiat.
-
Q&A
AZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.
-
Using the body as ‘a bioreactor’ — a regenerative medicine expert on where the field is headed
The director of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine believes the industry is “turning a corner.”
-
As drug shortages reach record highs, regulators float next steps
With many chemo and ADHD drugs stuck in stubborn shortages, several agencies are looking for new solutions to boost supplies.
-
FDA’s new diagnostic rules draw pharma criticism
Tests frequently used in clinical trials will soon be regulated like medical devices — with some exceptions.
-
Takeover target? Activist investor believes Novavax tech would be in ‘better hands’ with Big Pharma
With its next earnings report looming, pushback from an investor is adding pressure on Novavax to boost performance.
-
As AI proliferates in pharma, regulators look to catch up in clinical trials
The FDA’s newly launched Center for Clinical Trial Innovation potentially opens the door for more efficient and expanded AI use, but leaves pharmas wanting more guidance.
-
$4M+ gene therapies? How payers can adapt to a new reality of pricey ‘cures’
Pricey gene therapies promise great benefit to patients but pose a threat to the payer landscape — ICER and a Tufts think tank are offering potential solutions.
-
Profile
Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters
From its landmark CRISPR approval to its potential breakthrough drug for pain, Vertex’s development approach, led by chief scientific officer Dr. David Altshuler, is paying off.
-
4 offbeat biotechs making a splash in the life sciences
From resurrecting an extinct species to improving regenerative medicines with plant-based materials, these biotechs are on the leading edge of science.
-
As BMS announces major cuts, its Karuna deal looks poised to drive growth
The company's schizophrenia drug picked up in its $14 billion acquisition of Karuna Therapeutics recently generated positive long-term data from its phase 3 program.
-
Q&A
How a biotech exec is leveraging Big Pharma lessons to advance tRNA
Michelle Werner shares how the lessons from her resume — and personal experience — are driving her work with novel therapeutics.
-
Q&A
Neuroscience has entered a new era. Now it’s time for a ‘moonshot’ approach.
Dr. Jeremy Levin, CEO of Ovid Therapeutics, explains how scientific advances have converged to create a new era of drug development potential.
-
As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply
From popular weight loss drugs to lifesaving cancer therapies, recent pharma deals show the industry is doubling down on manufacturing capacity to meet demand.